> Last month, the United States Department of Justice (DOJ) announced a $39 million settlement agreement with pharmaceutical company, Daiichi Sankyo, Inc., resolving allegations that the company submitted false claims to federal healthcare programs by paying kickbacks to physicians to induce them to prescribe drugs. The DOJ alleged that Daiichi violated the Anti-Kickback Statute by disguising kickbacks as legitimate business engagements. Specifically, Daiichi engaged physicians as participants in various speaker programs, offering honoraria, payments, meals and other remuneration in return for the physicians’ services. The settlement agreement highlights the following activities which the DOJ found particularly offensive:
> 1. Honoraria was paid where recipient spoke only to members of his or her own staff in his or her own office.
https://www.frierlevitt.com/articles/service/pharmacylaw/pha...
> Last month, the United States Department of Justice (DOJ) announced a $39 million settlement agreement with pharmaceutical company, Daiichi Sankyo, Inc., resolving allegations that the company submitted false claims to federal healthcare programs by paying kickbacks to physicians to induce them to prescribe drugs. The DOJ alleged that Daiichi violated the Anti-Kickback Statute by disguising kickbacks as legitimate business engagements. Specifically, Daiichi engaged physicians as participants in various speaker programs, offering honoraria, payments, meals and other remuneration in return for the physicians’ services. The settlement agreement highlights the following activities which the DOJ found particularly offensive:
> 1. Honoraria was paid where recipient spoke only to members of his or her own staff in his or her own office.
> 2. [...]